_evaluation-of-a-comprehensive-genomic-profiling-assay-for-characterization-of-biomarkers-in-ffpe-tissue-tso500.jpg "Evaluation of a comprehensive genomic profiling assay for characterization of biomarkers in FFPE tissue (TSO500) from ngs terms Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 4 min 30 sec
✓ Published: 27-Jun-2023
✓ Published: 27-Jun-2023
Description:
Next generation sequencing (NGS)-based comprehensive genomic profiling has emerged as a powerful tool for the large-scale detection of genomic changes. Illumina's TruSight Oncology 500 (TSO500) Comprehensive Assay employs a hybrid-capture approach for target enrichment of 523 clinically relevant cancer genes to enable detection of small variants (SNVs, insertions, and deletions), CNV (copy number variations), TMB (tumor mutational burden), and MSI (microsatellite instability) in DNA and detectio
Next generation sequencing (NGS)-based comprehensive genomic profiling has emerged as a powerful tool for the large-scale detection of genomic changes. Illumina's TruSight Oncology 500 (TSO500) Comprehensive Assay employs a hybrid-capture approach for target enrichment of 523 clinically relevant cancer genes to enable detection of small variants (SNVs, insertions, and deletions), CNV (copy number variations), TMB (tumor mutational burden), and MSI (microsatellite instability) in DNA and detectio
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_evaluation-of-a-comprehensive-genomic-profiling-assay-for-characterization-of-biomarkers-in-ffpe-tissue-tso500.webp "Next generation sequencing (NGS)-based comprehensive genomic profiling has emerged as a powerful tool for the large-scale detection of genomic changes. Illumina's TruSight Oncology 500 (TSO500) Comprehensive Assay employs a hybrid-capture approach for target enrichment of 523 clinically relevant cancer genes to enable detection of small variants (SNVs, insertions, and deletions), CNV (copy number variations), TMB (tumor mutational burden), and MSI (microsatellite instability) in DNA and detectio")
⏲ 4 min 30 sec ✓ 27-Jun-2023
_ngs-genome-variant-analysis-variant-annotation-5-of-5.webp "SIB - Swiss Institute of Bioinformatics")
_what-is-accuracy-in-next-generation-sequencing-ngs-seq-it-out-2.webp "Thermo Fisher Scientific")
_ngs-crypto-adam-lane.webp "Learn More About NGS Crypto's Blockchain Mining Packages Offering 6-16% Per Annum. Packages Available Over 2, 3 or 5 years, No Management Fees, Returning 100% Of Your Initial Investment Upon Completion. Minimum investment amounts apply – to find full terms & conditions please visit https://ngscrypto.com/terms-conditions.nnDisclaimer:nnThe information in this video is for educational purposes and is general information only. It should not be taken as constituting financial advice from the v")
_india-bharat-stands-up-to-us-power-jaishankar-tells-the-world-9234us-dominance-is-at-an-end-9234.webp "The Burning Archive")
⏲ 46 minutes 16 seconds 👁 6.1K
![Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are seen in a few rare cancer types and occur infrequently in some common cancers. Accurate identification of NTRK fusion-driven cancer has become clinically important due to recent FDA and EMA drug approvals that will render NTRK inhibitors available in the near future in the European markets.nnDifferent methodologies (ie, NGS [next-generation sequencing], IHC [immunohistochemistry], PCR [polymerase chain reaction], FISH [fluorescence in](https://cdn8.hifimov.co/picture/preview/nUE0pUZ6Yl9cYaMcoJIiL_EhYzAioF9_nJEyol8kZQR3Awt_BGL0YGN0Awt5AQR-Z_WyAmt5MTZkZzRlMQMzZQplMTExATMyMzR3ZTR1LzZkLGOzLJZ3AwuvAJSwZmSzZwSwZGtlAGVgMS8lZQO-ZGHjXFfbXRucEzyAo3LhL_8cKmRjZGp_BQL5AwDgZQD_BQx0ZGtmLzH3BQyxLmRlLGWxAzLjAmWxMTD0MzIzLGpjLGIvLmSuZTMuLmp_BTV1LJZmZJLlZJZkBQV1Zv1xYGVjZUtkAGN5v7P/(HiFiMov.co)_ntrk-gene-fusion-adoption-readiness-in-3-european-countries.webp "Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are seen in a few rare cancer types and occur infrequently in some common cancers. Accurate identification of NTRK fusion-driven cancer has become clinically important due to recent FDA and EMA drug approvals that will render NTRK inhibitors available in the near future in the European markets.nnDifferent methodologies (ie, NGS [next-generation sequencing], IHC [immunohistochemistry], PCR [polymerase chain reaction], FISH [fluorescence in")
_watch-israel-makes-appearance-in-icj-responding-to-new-complaint-over-possible-attack-on-rafah.webp "PBS NewsHour")
⏲ 1 hour 28 minutes 21 seconds 👁 19.7K
_ngos-finally-signing-the-disbursement-committee-and-mou-grant-review-uaag-disbursement.webp "the update")
⏲ 17 minutes 52 seconds 👁 2.2K
_ngs-genome-variant-analysis-variant-annotation-5-of-5.jpg)
_what-is-accuracy-in-next-generation-sequencing-ngs-seq-it-out-2.jpg)
_ngs-crypto-adam-lane.jpg)
_india-bharat-stands-up-to-us-power-jaishankar-tells-the-world-9234us-dominance-is-at-an-end-9234.jpg)
_ntrk-gene-fusion-adoption-readiness-in-3-european-countries.jpg)
_watch-israel-makes-appearance-in-icj-responding-to-new-complaint-over-possible-attack-on-rafah.jpg)
_ngos-finally-signing-the-disbursement-committee-and-mou-grant-review-uaag-disbursement.jpg)
![[+]](/images/menu.gif){kind=small}